KJ-C2529
/ CARsgen
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 06, 2026
In vivo CAR-T product candidates in development
(The Manila Times)
- "KJ-C2529 is an in vivo CAR T-cell product candidate against CD19/CD20 deploying our CARvivo platform for the treatment of B-cell lymphoma. An IIT is expected to be initiated in 2026 for the treatment of R/R B-NHL."
New trial • B Cell Non-Hodgkin Lymphoma
1 to 1
Of
1
Go to page
1